The global chronic pulmonary hypertension treatment market is expected to garner a market value of US$ 7 billion in 2023 and is expected to accumulate a market value of US$ 11.4 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for chronic pulmonary hypertension treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.
The chronic pulmonary hypertension treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The global Chronic Pulmonary Hypertension Treatment market is expected to grow at a significant rate in the coming years due to an increasing prevalence of chronic PH and a growing demand for effective treatments. Factors such as rising healthcare expenditure and increasing awareness about the disease are also expected to drive market growth.
The market for chronic pulmonary hypertension treatment includes a range of products and services such as Medications, Oxygen therapy, Surgery, Lifestyle modifications and so on.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 7 billion |
| Anticipated Forecast Value (2033) | US$ 11.4 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Chronic Pulmonary Hypertension Treatment reflected a value CAGR of 3.5% during the historical period, 2018 to 2022. Patients with chronic PH require long-term treatment to manage their symptoms and improve their quality of life. As a result, there is a high demand for drugs and therapies that can effectively manage the disease.
The market is also expected to grow due to rising healthcare expenditure and increasing awareness about the disease. Governments and healthcare organizations are investing heavily in the development of new and improved treatments for chronic PH, which is expected to drive market growth. Furthermore, initiatives to raise awareness about the disease and improve early detection and diagnosis are also expected to contribute to market growth.
The development of new drugs and therapies is also expected to drive market growth. Pharmaceutical companies are investing heavily in research and development to develop new and innovative treatments for chronic PH. Overall, the market for Chronic Pulmonary Hypertension Treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Increasing incidence of chronic brain injuries to push the market growth
The chronic pulmonary hypertension treatment market is expected to experience significant growth in the coming years due to several factors. Chronic PH is a serious and life-threatening condition that affects the blood vessels in the lungs, causing high blood pressure and putting a strain on the heart. The disease can have a significant impact on the quality of life of patients and can lead to complications such as heart failure, respiratory failure, and death.
According to a report by the Centers for Disease Control and Prevention (CDC), the prevalence of PH in the United States is approximately 1% of the adult population, and the prevalence is increasing. The increasing prevalence of PH is attributed to various factors such as aging population, environmental pollution, smoking, and other medical conditions such as lung diseases, heart diseases, and connective tissue disorders.
As the prevalence of chronic PH increases, there is a growing demand for effective treatments that can help manage the disease and improve the quality of life of patients. This demand is driving the growth of the chronic pulmonary hypertension treatment market, as pharmaceutical companies are investing heavily in the development of new and innovative treatments for the disease.
Furthermore, initiatives to raise awareness about chronic PH and improve early detection and diagnosis are also contributing to market growth. Governments and healthcare organizations are investing in programs to educate healthcare providers and the general public about the disease and its risk factors, which is expected to lead to earlier detection and treatment of the disease.
In summary, the increasing prevalence of chronic pulmonary hypertension is a major driver of the growth of the chronic pulmonary hypertension treatment market, as there is a growing demand for effective treatments to manage the disease and improve the quality of life of patients.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for chronic pulmonary hypertension is often high and can be a significant barrier to accessing care. The high cost of drugs, diagnostic tests, and medical procedures can make it difficult for patients to afford treatment, especially in low-income countries or for uninsured patients.
Furthermore, while there are several treatments available for chronic pulmonary hypertension, there is still a significant unmet need for more effective and targeted therapies. Some patients may not respond well to existing treatments, and there is a need for new drugs and treatment strategies that can improve outcomes for these patients.
Increasing Prevalence of the Condition shaping landscape for Chronic Pulmonary Hypertension Treatment
The chronic pulmonary hypertension treatment market in the South & East Asia region is expected to experience significant growth in the coming years. This growth can be attributed to several factors, including the increasing prevalence of chronic pulmonary hypertension in the region and the growing demand for effective treatments.
South & East Asia is home to a large and growing population, and the region has a high burden of cardiovascular and respiratory diseases, which are risk factors for chronic pulmonary hypertension. According to a report by the Asia Pacific Society of Respirology, the prevalence of pulmonary hypertension in Asia is estimated to be between 15 to 25 cases per million population, and this prevalence is expected to increase in the coming years.
The demand for effective treatments for chronic pulmonary hypertension is also growing in the region. There is increasing awareness about the disease among healthcare providers and patients, which is leading to earlier diagnosis and treatment. The growing availability of treatment options, including drugs and medical devices, is also contributing to market growth.
Several pharmaceutical companies are investing in the development of new and innovative treatments for chronic pulmonary hypertension, which is expected to further drive market growth. For example, in 2020, United Therapeutics Corporation announced the launch of Tyvaso in Japan, a new inhaled treatment for pulmonary arterial hypertension.
Increasing Focus on technological advancements Shaping Landscape for Chronic Pulmonary Hypertension Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. The prevalence of chronic pulmonary hypertension is increasing in North America, which is driving demand for effective treatments. According to a report by the Centers for Disease Control and Prevention (CDC), approximately 10-15% of people in the United States with chronic obstructive pulmonary disease (COPD) also have pulmonary hypertension.
Advances in technology have led to the development of new and improved treatments for chronic pulmonary hypertension. For example, the introduction of prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors have revolutionized the treatment of pulmonary hypertension.
Overall, the chronic pulmonary hypertension treatment market in North America is expected to continue to grow due to the increasing prevalence of the disease, advancements in technology, government initiatives, increasing investments in research and development, and the growing aging population.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oral Medications to hold a significant share and push market growth
The oral segment is likely to account for a significant share of the market. This is because oral medications are more convenient and easier to administer compared to other routes of administration. They are also generally preferred by patients over injections or inhaled medications. Several oral medications such as endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogs are currently available for the treatment of chronic pulmonary hypertension.
In addition, the growing prevalence of chronic pulmonary hypertension, coupled with the increasing demand for effective treatments, is expected to drive the growth of the oral segment in the coming years.
Hospital Pharmacies to take the lead and drive market growth
Hospital pharmacies are likely to account for a significant share of the market. This is because hospital pharmacies are often the first point of contact for patients with chronic pulmonary hypertension, and they play a critical role in the management and treatment of the disease. Hospitals also have access to a wider range of medications and are more likely to have specialized pulmonary hypertension treatment centers and clinics.
In addition, hospital pharmacies often work closely with healthcare providers to ensure that patients receive the appropriate medications and dosages, and they may also provide education and support to patients and their families.
Key players in the market include companies such as Bayer, Attgeno AB, Cereno Scientific AB, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., along with healthcare providers and technology companies among other global players.
In June 2022, Gossamer Bio, Inc., a clinical-stage biopharmaceutical company that specializes in discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology, announced the release of crucial preclinical data that supports the potential of seralutinib in treating pulmonary arterial hypertension (PAH). The article, titled "Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension," is available online and will be included in a future printed edition of the European Respiratory Journal, which is the premier scientific journal of the European Respiratory Society.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 7 billion |
| Market Value in 2033 | US$ 11.4 billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Drug Type:
By Route of Administration:
By Distribution Channel:
By Region:
The chronic pulmonary hypertension treatment market size is valued at US$ 7 billion in 2023.
The chronic pulmonary hypertension treatment market is projected to thrive at a 5% CAGR through 2033.
The chronic pulmonary hypertension treatment market is predicted to surpass US$ 11.4 billion by 2033.
The oral segment leads the route of administration in the chronic pulmonary hypertension treatment market.
North America will gain nearly 40% of the chronic pulmonary hypertension treatment market share by 2033.
1. Executive Summary | Chronic Pulmonary Hypertension Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Injury Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Injury Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Injury Type, 2023 to 2033
5.3.1. Traumatic injuries
5.3.2. Acquired injuries
5.4. Y-o-Y Growth Trend Analysis By Injury Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Injury Type, 2023 to 2033
6. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
6.3.1. Imaging studies
6.3.2. Blood tests
6.3.3. Brain evaluations
6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
7. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Treatment , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment , 2023 to 2033
7.3.1. Occupational therapy
7.3.2. Physical therapy
7.3.3. Psychotherapy
7.3.4. Speech or language therapy
7.4. Y-o-Y Growth Trend Analysis By Treatment , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Treatment , 2023 to 2033
8. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
8.3.1. Hospitals
8.3.2. Neurology Clinics
8.3.3. Independent Pharmacies
8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
9. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Injury Type
10.2.3. By Diagnosis
10.2.4. By Treatment
10.2.5. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Injury Type
10.3.3. By Diagnosis
10.3.4. By Treatment
10.3.5. By End User
10.4. Key Takeaways
11. Latin America Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Injury Type
11.2.3. By Diagnosis
11.2.4. By Treatment
11.2.5. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Injury Type
11.3.3. By Diagnosis
11.3.4. By Treatment
11.3.5. By End User
11.4. Key Takeaways
12. Europe Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Injury Type
12.2.3. By Diagnosis
12.2.4. By Treatment
12.2.5. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Injury Type
12.3.3. By Diagnosis
12.3.4. By Treatment
12.3.5. By End User
12.4. Key Takeaways
13. South Asia Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Injury Type
13.2.3. By Diagnosis
13.2.4. By Treatment
13.2.5. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Injury Type
13.3.3. By Diagnosis
13.3.4. By Treatment
13.3.5. By End User
13.4. Key Takeaways
14. East Asia Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Injury Type
14.2.3. By Diagnosis
14.2.4. By Treatment ;
14.2.5. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Injury Type
14.3.3. By Diagnosis
14.3.4. By Treatment
14.3.5. By End User
14.4. Key Takeaways
15. Oceania Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Injury Type
15.2.3. By Diagnosis
15.2.4. By Treatment
15.2.5. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Injury Type
15.3.3. By Diagnosis
15.3.4. By Treatment
15.3.5. By End User
15.4. Key Takeaways
16. MEA Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Injury Type
16.2.3. By Diagnosis
16.2.4. By Treatment
16.2.5. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Injury Type
16.3.3. By Diagnosis
16.3.4. By Treatment
16.3.5. By End User
16.4. Key Takeaways
17. Key Countries Chronic Brain Damage Management Market Analysis
17.1. U.S.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Injury Type
17.1.2.2. By Diagnosis
17.1.2.3. By Treatment
17.1.2.4. By End User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Injury Type
17.2.2.2. By Diagnosis
17.2.2.3. By Treatment
17.2.2.4. By End User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Injury Type
17.3.2.2. By Diagnosis
17.3.2.3. By Treatment
17.3.2.4. By End User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Injury Type
17.4.2.2. By Diagnosis
17.4.2.3. By Treatment
17.4.2.4. By End User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Injury Type
17.5.2.2. By Diagnosis
17.5.2.3. By Treatment
17.5.2.4. By End User
17.6. U.K.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Injury Type
17.6.2.2. By Diagnosis
17.6.2.3. By Treatment
17.6.2.4. By End User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Injury Type
17.7.2.2. By Diagnosis
17.7.2.3. By Treatment
17.7.2.4. By End User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Injury Type
17.8.2.2. By Diagnosis
17.8.2.3. By Treatment
17.8.2.4. By End User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Injury Type
17.9.2.2. By Diagnosis
17.9.2.3. By Treatment
17.9.2.4. By End User
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Injury Type
17.10.2.2. By Diagnosis
17.10.2.3. By Treatment
17.10.2.4. By End User
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Injury Type
17.11.2.2. By Diagnosis
17.11.2.3. By Treatment
17.11.2.4. By End User
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Injury Type
17.12.2.2. By Diagnosis
17.12.2.3. By Treatment
17.12.2.4. By End User
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Injury Type
17.13.2.2. By Diagnosis
17.13.2.3. By Treatment
17.13.2.4. By End User
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Injury Type
17.14.2.2. By Diagnosis
17.14.2.3. By Treatment
17.14.2.4. By End User
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Injury Type
17.15.2.2. By Diagnosis
17.15.2.3. By Treatment
17.15.2.4. By End User
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Injury Type
17.16.2.2. By Diagnosis
17.16.2.3. By Treatment
17.16.2.4. By End User
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Injury Type
17.17.2.2. By Diagnosis
17.17.2.3. By Treatment
17.17.2.4. By End User
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Injury Type
17.18.2.2. By Diagnosis
17.18.2.3. By Treatment
17.18.2.4. By End User
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Injury Type
17.19.2.2. By Diagnosis
17.19.2.3. By Treatment
17.19.2.4. By End User
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Injury Type
17.20.2.2. By Diagnosis
17.20.2.3. By Treatment
17.20.2.4. By End User
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Injury Type
17.21.2.2. By Diagnosis
17.21.2.3. By Treatment
17.21.2.4. By End User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Injury Type
18.3.3. By Diagnosis
18.3.4. By Treatment
18.3.5. By End User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. NeuroVive Pharmaceutical AB
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. TEVA Pharmaceutical Industries Ltd.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Integra LifeSciences Corporation
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Medtronic PLC
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Neuren Pharmaceuticals Ltd.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Johnson & Johnson Services Inc.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Smith & Nephew
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Stryker
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. B.Braun Melsungen AG
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Neural Analytics, Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Chronic Pulmonary Hypertension Treatment Market
